预制成型牛心包补片移植物在感染性主动脉/髂动脉病变中的围手术期与中期结果
本研究回顾性分析2020至2023年单中心26例患者共27次开放手术,使用预制成型牛心包补片移植物治疗感染性主动脉、主髂或髂动脉病变。技术成功率为88.9%,30天死亡率为14.8%,1年原发和辅助原发通畅率分别为85.2%和96.3%。结论认为预制成型牛心包补片移植物是治疗感染性主髂动脉病变的可行选择。
要点
- 预制成型牛心包补片移植物可用于感染性主动脉/髂动脉病变的开放重建。
- 30天死亡率为14.8%,1年原发和辅助原发通畅率分别为85.2%和96.3%。
- 该移植物具有货架可用、无取材并发症和潜在节省手术时间的优势。
核心结论
- 预制成型牛心包补片移植物是治疗感染性主髂动脉病变的可行选择,中期结果良好。
研究设计与样本
- 回顾性单中心结局分析,纳入2020至2023年连续26例患者共27次开放手术,使用预制成型牛心包补片移植物治疗感染性主动脉、主髂或髂动脉病变。
主要发现
- 技术成功(包括完全移除移植物、广泛清创、成功血管重建和无移植物相关30天死亡)达到24例(88.9%)。
- 30天死亡4例(14.8%),原因为脓毒症或心脏事件。
- 中位随访18个月(IQR 14,范围11-25),1年原发通畅率为85.2%,辅助原发通畅率为96.3%。
- 18例(66.7%)患者存在血管感染危险因素,主要为近期血管操作和近期远隔部位感染。
临床怎么用
- 对于感染性主动脉/髂动脉病变,预制成型牛心包补片移植物可作为开放手术重建的选项之一。
- 其货架可用、无取材并发症和潜在节省手术时间的优势可能有利于急诊或感染条件下使用。
局限性
- 回顾性单中心设计,样本量小(26例患者,27次手术),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Native or graft-associated aortoiliac infections are rare but associated with a high morbidity and mortality. Prefabricated straight or bifurcated bovine pericardial grafts are among the available open surgical reconstruction options. To date, only few data on the short- and midterm outcomes have been published. The aim of the present study was to analyze the outcomes of surgery in infected aortic, aortoiliac, and iliac pathologies at our center using prefabricated bovine pericardial grafts. METHODS: Retrospective, single-center outcome analysis of all consecutive patients who underwent open surgical repair between 2020 and 2023 with a factory-presewn bovine pericardial graft for aortic, aortoiliac, and iliac infectious disease at a university-affiliated tertiary care hospital. Primary outcome were bovine pericardial graft-associated morbidity and mortality. RESULTS: During the study period, 26 patients underwent 27 open surgical aortic, aortoiliac, or iliac reconstructions using a straight or bifurcated BioModiVasc® Perima™ (BioModiVasc Inc., Mississauga, Ontario, Canada) bovine pericardial graft due to an infective native aortic aneurysm, vascular graft or endograft infection, trauma with contamination, acute Leriche syndrome with adjacent infection, or recurrence of soft tissue sarcoma excision. Risk factors for vascular infections, mainly recent vascular procedure and recent infection at a remote site, were detected in n = 18 (66.7%) patients. Technical success, defined as complete graft removal (in graft infections), extensive débridement, successful vessel reconstruction, and no bovine pericardial graft-related early (30-day) mortality, was achieved in n = 24 (88.9%) cases. Median follow-up was 18 months (11-25, IQR 14). Thirty-day mortality was n = 4 (14.8%), due to sepsis or cardiac events. At 1 year, primary and assisted primary patency rates were 85.2% and 96.3%, respectively. CONCLUSION: Prefabricated bovine pericardial grafts are a viable option in the treatment of infectious aortoiliac pathologies. Apart from favorable midterm results, their off-the-shelf availability, the lack of harvesting morbidity, and the potential sparing of operating time are main advantages.
引用
- Celi de la Torre JA, Jakober N, Jung G, et al. Perioperative and Mid-term Outcome of Prefabricated Bovine Pericardial Grafts in the Context of Infected Aortic/Iliac Pathologies. Ann Vasc Surg. 2025. PMID: 40582455. doi:10.1016/j.avsg.2025.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。